FDA Grants RMAT Designation to Tenaya's TN-401 Gene Therapy for PKP2-ARVC
TNYA sits 20% above its 52-week low of $0.532.
Summary
Tenaya Therapeutics received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for TN-401, its gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. The designation is supported by positive interim data from the RIDGE-1 Phase 1b/2 trial showing reduced arrhythmia burden. RMAT provides enhanced FDA interaction and potential for accelerated approval, priority review, and rolling review. This follows prior Fast Track and Orphan Drug designations, strengthening the regulatory pathway. Additional data and regulatory updates are expected in Q4 2026. The company faces Nasdaq delisting risk and high dilution, but this milestone validates the clinical program.
At the time of this announcement, TNYA was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $143.5M. The 52-week trading range was $0.53 to $2.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.